Anavex Life Sciences (AVXL) Financials

$8.21 -0.70 (-7.82%)

Closing price 03:59 PM Eastern

Extended Trading

$8.30 +0.09 (+1.06%)

As of 07:56 PM Eastern

Annual Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	9/30/2022	9/30/2023	9/30/2024
Net Income / (Loss) Attributable to Common Shareholders	-48	-48	-43
Consolidated Net Income / (Loss)	-48	-48	-43
Net Income / (Loss) Continuing Operations	-48	-48	-43
Total Pre-Tax Income	-48	-47	-43
Total Operating Income	-51	-56	-53
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	51	56	53
Selling, General & Admin Expense	13	12	11
Research & Development Expense	38	44	42
Total Other Income / (Expense), net	3.37	8.26	9.88
Interest Expense	-0.95	-6.52	-7.32
Interest & Investment Income	3.32	2.72	2.29
Other Income / (Expense), net	-0.90	-0.98	0.26
Income Tax Expense	0.36	0.01	0.00
Basic Earnings per Share	-	($0.60)	($0.52)
Weighted Average Basic Shares Outstanding	-0.62	79.79M	83.47M
Diluted Earnings per Share	-	($0.60)	($0.52)
Weighted Average Diluted Shares Outstanding	-0.62	79.79M	83.47M
Weighted Average Basic & Diluted Shares Outstanding	-0.62	82.09M	84.82M

This table shows Anavex Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-14	-13	-13	-11	-10	-8.62	-11	-12	-12	-12
Consolidated Net Income / (Loss)	-12	-14	-13	-13	-11	-10	-8.62	-11	-12	-12	-12
Net Income / (Loss) Continuing Operations	-12	-14	-13	-13	-11	-10	-8.62	-11	-12	-12	-12
Total Pre-Tax Income	-12	-14	-13	-13	-11	-10	-8.62	-10	-12	-12	-12
Total Operating Income	-12	-15	-15	-14	-14	-13	-11	-13	-15	-14	-14
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	12	15	15	14	14	13	11	13	15	14	14
Selling, General & Admin Expense	3.19	3.90	3.32	2.88	3.25	2.59	2.69	2.79	2.86	2.78	3.15
Research & Development Expense	9.27	11	12	11	10	10	8.68	9.73	12	12	10
Total Other Income / (Expense), net	0.18	1.20	2.39	1.13	2.29	2.44	2.76	2.08	2.45	2.59	1.48
Interest Expense	-0.23	-0.70	-1.27	-1.47	-1.83	-1.96	-2.01	-1.76	-1.86	-1.70	-1.39
Interest & Investment Income	0.68	0.99	0.73	0.75	0.57	0.67	0.59	0.47	0.53	0.70	0.41
Other Income / (Expense), net	-0.73	-0.50	0.39	-1.08	-0.10	-0.19	0.16	-0.15	0.07	0.19	-0.33
Basic Earnings per Share	-	-	-	($0.17)	($0.14)	-	($0.11)	($0.13)	($0.14)	-	($0.14)
Weighted Average Basic Shares Outstanding	-0.16	-0.62	77.98M	78.30M	80.88M	79.79M	82.08M	82.46M	84.54M	83.47M	84.81M
Diluted Earnings per Share	-	-	-	($0.17)	($0.14)	-	($0.11)	($0.13)	($0.14)	-	($0.14)
Weighted Average Diluted Shares Outstanding	-0.16	-0.62	77.98M	78.30M	80.88M	79.79M	82.08M	82.46M	84.54M	83.47M	84.81M
Weighted Average Basic & Diluted Shares Outstanding	77.44M	-0.62	77.98M	78.30M	-0.14	82.09M	82.11M	84.64M	84.80M	84.82M	85.06M

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	9/30/2022	9/30/2023	9/30/2024
Net Change in Cash & Equivalents	-2.95	1.87	-19
Net Cash From Operating Activities	-24	-28	-31
Net Cash From Continuing Operating Activities	-24	-28	-31
Net Income / (Loss) Continuing Operations	-48	-48	-43
Consolidated Net Income / (Loss)	-48	-48	-43
Non-Cash Adjustments To Reconcile Net Income	18	17	9.36
Changes in Operating Assets and Liabilities, net	5.36	2.51	2.83
Net Cash From Investing Activities	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	0.00	0.00	0.00
Net Cash From Financing Activities	21	30	12
Net Cash From Continuing Financing Activities	21	30	12
Issuance of Common Equity	21	28	11
Other Financing Activities, net	1.01	1.78	0.69

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-0.14	-4.04	-5.54	9.85	1.35	-3.79	-7.26	-4.38	-0.63	-6.57	-11
Net Cash From Operating Activities	-7.05	-4.04	-5.79	-8.49	-7.65	-5.85	-7.32	-12	-5.18	-6.66	-12
Net Cash From Continuing Operating Activities	-7.05	-4.04	-5.79	-8.49	-7.65	-5.85	-7.32	-12	-5.18	-6.66	-12
Net Income / (Loss) Continuing Operations	-12	-14	-13	-13	-11	-10	-8.62	-11	-12	-12	-12
Consolidated Net Income / (Loss)	-12	-14	-13	-13	-11	-10	-8.62	-11	-12	-12	-12
Non-Cash Adjustments To Reconcile Net Income	3.99	6.04	5.35	4.82	3.87	3.19	2.29	2.65	2.43	2.00	2.06
Changes in Operating Assets and Liabilities, net	1.33	4.20	1.83	-0.20	-0.24	1.11	-0.98	-3.76	4.61	2.97	-2.06
Net Cash From Investing Activities	-	-	0.00	-	-	-	0.00	-	-	-	0.00
Net Cash From Continuing Investing Activities	-	-	0.00	-	-	-	0.00	-	-	-	0.00
Net Cash From Financing Activities	6.91	0.00	0.26	18	9.00	2.06	0.06	7.28	4.55	0.09	0.71
Net Cash From Continuing Financing Activities	6.91	0.00	0.26	18	9.00	2.06	0.06	7.28	4.55	0.09	0.71
Other Financing Activities, net	0.51	-0.00	0.26	0.18	0.47	0.87	0.06	0.10	0.44	0.09	0.71

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	9/30/2022	9/30/2023	9/30/2024
Total Assets	153	154	136
Total Current Assets	153	152	133
Cash & Equivalents	149	151	132
Prepaid Expenses	0.35	0.65	0.93
Plant, Property, & Equipment, net	0.00	0.00	0.00
Total Noncurrent Assets	0.00	2.71	2.45
Noncurrent Note & Lease Receivables	-	2.71	2.45
Total Liabilities & Shareholders' Equity	153	154	136
Total Liabilities	10	13	15
Total Current Liabilities	9.77	12	14
Accounts Payable	3.83	4.32	9.63
Accrued Expenses	5.95	7.30	4.84
Total Noncurrent Liabilities	0.44	0.92	0.84
Other Noncurrent Operating Liabilities	0.44	-	0.84
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	142	142	120
Total Preferred & Common Equity	142	142	120
Preferred Stock	0.00	0.00	0.00
Total Common Equity	142	142	120
Common Stock	388	435	456
Retained Earnings	-246	-293	-336

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	12/31/2022	3/31/2023	6/30/2023	12/31/2023	3/31/2024	6/30/2024	12/31/2024
Total Assets	160	148	159	158	148	145	142	124
Total Current Assets	160	148	159	156	145	141	142	121
Cash & Equivalents	153	144	153	155	144	139	139	121
Prepaid Expenses	0.46	0.66	0.98	0.83	0.76	1.35	1.06	0.71
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	0.00	0.00	0.00	2.17	3.55	3.79	0.00	2.56
Noncurrent Note & Lease Receivables	-	-	-	2.17	3.55	3.79	-	2.56
Total Liabilities & Shareholders' Equity	160	148	159	158	148	145	142	124
Total Liabilities	9.48	13	14	11	12	9.56	12	13
Total Current Liabilities	9.48	12	13	10	12	8.64	11	12
Accounts Payable	3.13	5.29	6.28	4.15	4.29	3.73	3.50	4.57
Accrued Expenses	5.91	7.04	6.82	5.99	7.29	4.92	7.33	7.73
Total Noncurrent Liabilities	0.00	0.92	0.92	0.92	0.92	0.92	0.92	0.83
Other Noncurrent Operating Liabilities	-	0.92	0.92	0.92	0.92	0.92	0.92	0.83
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	151	135	145	147	136	135	130	111
Total Preferred & Common Equity	151	135	145	147	136	135	130	111
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	151	135	145	147	136	135	130	111
Common Stock	382	394	417	430	437	447	454	459
Retained Earnings	-231	-259	-272	-283	-302	-312	-324	-348

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric	2022	2023	2024
Period end date	9/30/2022	9/30/2023	9/30/2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-22.92%	-9.34%	7.27%
EBIT Growth	-22.92%	-9.34%	7.27%
NOPAT Growth	-21.39%	-9.36%	5.16%
Net Income Growth	-26.56%	0.99%	9.48%
EPS Growth	0.00%	0.00%	13.33%
Operating Cash Flow Growth	20.23%	-14.63%	-10.89%
Free Cash Flow Firm Growth	-0.63%	-20.49%	6.19%
Invested Capital Growth	-416.97%	-37.57%	-30.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-6.67%	4.93%	-2.55%
EBIT Q/Q Growth	-6.67%	4.93%	-2.55%
NOPAT Q/Q Growth	-6.32%	4.51%	-3.29%
Net Income Q/Q Growth	-5.66%	8.02%	-3.55%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	13.03%	-6.95%	-2.70%
Free Cash Flow Firm Q/Q Growth	3.83%	-3.55%	1.89%
Invested Capital Q/Q Growth	-170.71%	-13.76%	-32.86%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.75%	100.01%	100.00%
Interest Burden Percent	91.77%	83.72%	81.73%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-32.72%	-33.41%	-32.81%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-32.72%	-33.41%	-32.81%
Return on Equity Simple (ROE_SIMPLE)	-33.67%	-33.49%	-35.76%
Net Operating Profit after Tax (NOPAT)	-36	-39	-37
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-8.16%	-5.65%	-4.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-27.51%	-30.78%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-52	-57	-53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-52	-57	-53
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	5.65	3.78	4.00
Price to Tangible Book Value (P/TBV)	5.65	3.78	4.00
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.03	-1.06	-1.08
Leverage Ratio	1.07	1.08	1.11
Compound Leverage Factor	0.98	0.90	0.90
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	45.00	22.91	15.18
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	15.63	13.06	9.20
Quick Ratio	15.27	13.00	9.14
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-30	-37	-34
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-6.67	-9.17	-12
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-5.38	-2.51	-2.75
Enterprise Value (EV)	655	386	349
Market Capitalization	804	537	482
Book Value per Share	$1.83	$1.73	$1.42
Tangible Book Value per Share	$1.83	$1.73	$1.42
Total Capital	142	142	120
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-149	-151	-132
Capital Expenditures (CapEx)	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-6.22	-11	-14
Debt-free Net Working Capital (DFNWC)	143	140	119
Net Working Capital (NWC)	143	140	119
Net Nonoperating Expense (NNE)	12	8.48	5.99
Net Nonoperating Obligations (NNO)	-149	-151	-132
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.52)
Adjusted Weighted Average Basic Shares Outstanding	77.96M	82.09M	83.47M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.52)
Adjusted Weighted Average Diluted Shares Outstanding	77.96M	82.09M	83.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	76.91M	82.09M	84.82M
Normalized Net Operating Profit after Tax (NOPAT)	-36	-39	-37
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.47%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-14.54%	-25.88%	-28.50%	-35.74%	-3.34%	18.64%	25.15%	17.04%	-7.56%	-10.18%	-24.02%
EBIT Growth	-14.54%	-25.88%	-28.50%	-35.74%	-3.34%	18.64%	25.15%	17.04%	-7.56%	-10.18%	-24.02%
NOPAT Growth	-9.30%	-24.74%	-31.22%	-23.18%	-8.61%	17.23%	26.04%	11.78%	-8.85%	-13.32%	-19.46%
Net Income Growth	-21.49%	-21.95%	-19.20%	-25.57%	8.79%	29.00%	33.53%	19.54%	-8.28%	-14.53%	-40.47%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	23.53%	0.00%	0.00%	-27.27%
Operating Cash Flow Growth	6.22%	47.31%	-65.50%	11.94%	-8.50%	-44.63%	-26.30%	-37.31%	32.31%	-13.83%	-65.62%
Free Cash Flow Firm Growth	36.47%	42.78%	-57.20%	60.31%	41.97%	-19.34%	-17.34%	-356.45%	-142.72%	-14.68%	5.17%
Invested Capital Growth	-494.41%	-416.97%	-77.83%	-629.83%	-227.38%	-37.57%	3.62%	46.66%	-11.32%	-30.00%	-20.39%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-17.24%	-19.62%	4.98%	-1.86%	10.74%	5.82%	12.59%	-13.76%	-15.73%	3.53%	1.61%
EBIT Q/Q Growth	-17.24%	-19.62%	4.98%	-1.86%	10.74%	5.82%	12.59%	-13.76%	-15.73%	3.53%	1.61%
NOPAT Q/Q Growth	-8.15%	-22.68%	-0.65%	7.76%	4.64%	6.50%	10.06%	-10.86%	-17.65%	2.67%	5.19%
Net Income Q/Q Growth	-18.49%	-15.55%	9.23%	-1.04%	13.94%	10.05%	15.02%	-22.32%	-15.82%	4.86%	-4.23%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	17.65%	0.00%	0.00%	0.00%	-7.69%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	26.83%	42.67%	-43.27%	-46.51%	9.85%	23.57%	-25.12%	-59.28%	55.56%	-28.53%	-82.04%
Free Cash Flow Firm Q/Q Growth	4.34%	20.25%	-32.47%	60.73%	-39.85%	-64.02%	-30.26%	-53.87%	25.63%	22.50%	-7.71%
Invested Capital Q/Q Growth	-116.50%	-170.71%	-27.46%	2.30%	2.88%	-13.76%	10.71%	45.93%	-102.69%	-32.86%	17.31%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.72%	101.49%	99.85%	100.38%	100.36%	99.37%	100.00%	101.01%	99.45%	98.95%	100.00%
Interest Burden Percent	93.08%	89.23%	86.65%	85.50%	82.45%	79.53%	76.83%	82.41%	83.76%	83.02%	87.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-29.50%	-32.72%	-35.57%	-35.47%	-34.72%	-33.41%	-31.88%	-28.98%	-30.03%	-32.81%	-37.72%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-29.50%	-32.72%	-35.57%	-35.47%	-34.72%	-33.41%	-31.88%	-28.98%	-30.03%	-32.81%	-37.72%
Return on Equity Simple (ROE_SIMPLE)	-30.12%	0.00%	-37.05%	-36.33%	-35.19%	0.00%	-31.83%	-30.08%	-32.00%	0.00%	-41.92%
Net Operating Profit after Tax (NOPAT)	-8.72	-11	-11	-9.93	-9.47	-8.86	-7.96	-8.76	-10	-10	-9.51
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-2.35%	-2.38%	-1.49%	-2.07%	-1.17%	-0.86%	-0.46%	-1.22%	-1.30%	-1.12%	-1.96%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-6.24%	-5.87%	-	-	-8.34%	-8.58%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-13	-16	-15	-15	-14	-13	-11	-13	-15	-14	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-16	-15	-15	-14	-13	-11	-13	-15	-14	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.14	5.65	5.34	4.61	4.48	3.78	5.63	3.10	2.75	4.00	8.21
Price to Tangible Book Value (P/TBV)	5.14	5.65	5.34	4.61	4.48	3.78	5.63	3.10	2.75	4.00	8.21
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-1.03	-1.05	-1.03	-1.04	-1.06	-1.06	-1.05	-1.06	-1.08	-1.07
Leverage Ratio	1.06	1.07	1.08	1.07	1.07	1.08	1.10	1.08	1.08	1.11	1.10
Compound Leverage Factor	0.99	0.96	0.94	0.92	0.88	0.86	0.84	0.89	0.91	0.92	0.96
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	47.85	45.78	31.02	27.01	33.98	23.85	34.61	24.02	15.79	16.12	38.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	16.89	15.63	12.03	12.15	15.35	13.06	12.48	16.29	13.06	9.20	9.88
Quick Ratio	16.15	15.27	11.65	11.71	15.27	13.00	12.42	16.13	12.80	9.14	9.82
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.67	-5.32	-7.05	-2.77	-3.87	-6.35	-8.27	-13	-9.40	-7.28	-7.84
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-2.46	-6.67	-8.50	-8.30	-8.06	-9.17	-8.19	-4.43	-8.98	-12	-9.86
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-2.05	-5.38	-3.72	-7.16	-5.60	-2.51	0.31	3.87	-0.91	-2.75	-1.67
Enterprise Value (EV)	622	655	578	515	502	386	619	279	218	349	790
Market Capitalization	775	804	722	669	657	537	763	418	357	482	911
Book Value per Share	$1.95	$1.83	$1.73	$1.86	$1.82	$1.73	$1.65	$1.64	$1.53	$1.42	$1.31
Tangible Book Value per Share	$1.95	$1.83	$1.73	$1.86	$1.82	$1.73	$1.65	$1.64	$1.53	$1.42	$1.31
Total Capital	151	142	135	145	147	142	136	135	130	120	111
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-153	-149	-144	-153	-155	-151	-144	-139	-139	-132	-121
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.46	-6.22	-7.58	-7.39	-9.31	-11	-11	-7.30	-8.06	-14	-12
Debt-free Net Working Capital (DFNWC)	151	143	136	146	146	140	133	132	131	119	109
Net Working Capital (NWC)	151	143	136	146	146	140	133	132	131	119	109
Net Nonoperating Expense (NNE)	3.65	3.59	2.20	3.17	1.81	1.29	0.66	1.78	1.90	1.58	2.60
Net Nonoperating Obligations (NNO)	-153	-149	-144	-153	-155	-151	-144	-139	-139	-132	-121
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	$0.00	($0.17)	($0.17)	$0.00	$0.00	$0.00	($0.13)	($0.14)	$0.00	($0.14)
Adjusted Weighted Average Basic Shares Outstanding	77.94M	-1.00	78.03M	80.84M	81.95M	79.79M	82.11M	82.46M	84.54M	83.47M	84.81M
Adjusted Diluted Earnings per Share	($0.16)	$0.00	($0.17)	($0.17)	$0.00	$0.00	$0.00	($0.13)	($0.14)	$0.00	($0.14)
Adjusted Weighted Average Diluted Shares Outstanding	77.94M	-1.00	78.03M	80.84M	81.95M	79.79M	82.11M	82.46M	84.54M	83.47M	84.81M
Adjusted Basic & Diluted Earnings per Share	($0.16)	$0.00	($0.17)	($0.17)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.44M	-1.00	77.98M	78.30M	80.88M	82.09M	82.11M	84.64M	84.80M	84.82M	85.06M
Normalized Net Operating Profit after Tax (NOPAT)	-8.72	-11	-11	-9.93	-9.47	-8.86	-7.96	-8.76	-10	-10	-9.51
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-1.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Anavex Life Sciences' Financials

When does Anavex Life Sciences's fiscal year end?

According to the most recent income statement we have on file, Anavex Life Sciences' financial year ends in September. Their financial year 2024 ended on September 30, 2024.

How has Anavex Life Sciences' net income changed over the last 2 years?

Anavex Life Sciences' net income appears to be on a downward trend, with a most recent value of -$43.00 million in 2024, falling from -$47.98 million in 2022. The previous period was -$47.51 million in 2023. View Anavex Life Sciences' forecast to see where analysts expect Anavex Life Sciences to go next.

What is Anavex Life Sciences's operating income?

Anavex Life Sciences's total operating income in 2024 was -$52.88 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $52.88 million

How has Anavex Life Sciences revenue changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Anavex Life Sciences have?

Anavex Life Sciences' total liabilities were at $15.30 million at the end of 2024, a 22.1% increase from 2023, and a 49.8% increase since 2022.

How much cash does Anavex Life Sciences have?

In the past 2 years, Anavex Life Sciences' cash and equivalents has ranged from $132.19 million in 2024 to $151.02 million in 2023, and is currently $132.19 million as of their latest financial filing in 2024.

How has Anavex Life Sciences' book value per share changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' book value per share changed from 1.83 in 2022 to 1.42 in 2024, a change of -22.4%.

Related Companies

This page (NASDAQ:AVXL) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Financials

Frequently Asked Questions About Anavex Life Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Financials

Annual Income Statements for Anavex Life Sciences

Quarterly Income Statements for Anavex Life Sciences

Annual Cash Flow Statements for Anavex Life Sciences

Quarterly Cash Flow Statements for Anavex Life Sciences

Annual Balance Sheets for Anavex Life Sciences

Quarterly Balance Sheets for Anavex Life Sciences

Annual Metrics and Ratios for Anavex Life Sciences

Quarterly Metrics and Ratios for Anavex Life Sciences

Frequently Asked Questions About Anavex Life Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools